Jaringan Laboratorium Medis

Vol. 7 No. 1 (2025): May 2025
Original Articles

Differences in TNF-α Levels in Pulmonary Tuberculosis Patients Before and After One Month of Anti-Tuberculosis Drug Therapy

PDF
  • Rachmad Bayu Kuncara,
  • Devi Etivia Purlinda,
  • Yoki Setyaji,
  • Wiwit Sulistyasmi
Rachmad Bayu Kuncara
Poltekkes Kemenkes Semarang
Devi Etivia Purlinda
Poltekkes Kemenkes Semarang
Yoki Setyaji
Poltekkes Kemenkes Semarang

Published 2025-05-01

Keywords

  • Pulmonary Tuberculosis ; Anti-Tuberculosis Drugs ; TNF-α

Copyright (c) 2025 Jaringan Laboratorium Medis

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

How to Cite

Differences in TNF-α Levels in Pulmonary Tuberculosis Patients Before and After One Month of Anti-Tuberculosis Drug Therapy. (2025). Jaringan Laboratorium Medis, 7(1), 38-43. https://doi.org/10.31983/jlm.v7i1.12789

CrossMark



Dimensions

If it doesn't Appear, click here



PlumX Metrics



Impact Factor

or, Visit on here

Abstract

Pulmonary tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. Patients diagnosed with pulmonary tuberculosis undergo Anti-Tuberculosis Drug (OAT) therapy for six months. In the first two months, known as the intensive phase, patients receive a combination of OATs such as isoniazid, rifampicin, ethambutol, and pyrazinamide. TNF-α is a pro-inflammatory cytokine that plays a crucial role in granuloma formation to contain the spread of Mycobacterium tuberculosis. This study aims to determine the difference in TNF-α levels in pulmonary tuberculosis patients before and after one month of OAT therapy. The study used an observational analytic design with a prospective cohort approach without comparison. A total of 17 newly diagnosed pulmonary tuberculosis patients at Bangetayu, Kedungmundu, and Tlogosari Wetan Health Centers, Semarang City, were included. TNF-α levels in serum samples were measured using the ELISA method. The mean TNF-α level before OAT therapy was 110.09±100,48 pg/mL, while after one month of therapy, it decreased to 90,05±60,12 pg/mL. The statistical analysis using the Mann-Whitney test yielded a p-value of 0.228 (p > 0.05), indicating that there was no statistically significant difference in TNF-α levels before and after one month of anti-tuberculosis drug (OAT) therapy. However, the mean TNF-α levels showed a decreasing trend, which, although not statistically significant, may suggest an initial immunological response to the treatment. The researcher recommends further studies with a larger sample size and longer observation period—such as until the end of the intensive phase or the completion of therapy—in order to obtain more representative and statistically significant results regarding TNF-α dynamics during tuberculosis treatment.

PDF

Downloads

Download data is not yet available.

References

  1. Beig, T. Y., Khan, U. H., Ganie, B. A., Tahir, S., Shah, S., & Dhobi, G. N. (2023). Correlation Between Serum Tumor Necrosis Factor-Alpha (TNF-α) and Clinical Severity of Tuberculosis: A Hospital-Based Study. Cureus, 10(2). https://doi.org/10.7759/cureus.35626
  2. Cao, Y., Wang, X., Liu, P., Su, Y., Yu, H., & Du, J. (2022). Vitamin D and the risk of latent tuberculosis infection: a systematic review and meta-analysis. BMC Pulmonary Medicine, 22(1), 1–10. https://doi.org/10.1186/s12890-022-01830-5
  3. Carabalí-Isajar, M. L., Rodríguez-Bejarano, O. H., Amado, T., Patarroyo, M. A., Izquierdo, M. A., Lutz, J. R., & Ocampo, M. (2023). Clinical manifestations and immune response to tuberculosis. World Journal of Microbiology and Biotechnology, 39(8), 1–26. https://doi.org/10.1007/s11274-023-03636-x
  4. Cheng, C., Pan, W., Li, X., & Qu, H. (2020). Clinical effect of vitamin D supplementation on patients with pulmonary tuberculosis and its influence on the expression of immune cells and inflammatory factors. Experimental and Therapeutic Medicine, 20, 2236–2244. https://doi.org/10.3892/etm.2020.8957
  5. Fortuna, T. A., Rachmawati, H., Hasmono, D., & Karuniawati, H. (2022). Studi Penggunaan Obat Anti Tuberkulosis (OAT) Tahap Lanjutan pada Pasien Baru BTA Positif. Pharmacon: Jurnal Farmasi Indonesia, 19(1), 62–71. https://doi.org/10.23917/pharmacon.v19i1.17907
  6. Hejazi, M. E., Ahmadzadeh, A., Khabbazi, A., Ebrahimi, A., Farmani, M., & Hejazi, Y. (2020). Tuberculin skin test conversion in patients under treatment with anti-tumor necrotizing factor alpha agents. BMC Infectious Diseases, 20(1), 4–9. https://doi.org/10.1186/s12879-020-05166-5
  7. Joshi, L., Ponnana, M., Sivangala, R., Chelluri, L. K., Nallari, P., Penmetsa, S., Valluri, V., & Gaddam, S. (2015). Evaluation of TNF-α, il-10 and il-6 cytokine production and their correlation with genotype variants amongst tuberculosis patients and their household contacts. PLoS ONE, 10(9), 1–15. https://doi.org/10.1371/journal.pone.0137727
  8. Kemenkes RI. (2021). Profil Kesehatan Indonesia 2021.
  9. Kuncara, R. B., & Najiah, D. Z. (2024). Perbedaan Kadar Vitamin D3 pada Penderita Tuberkulosis Paru Sebelum dan Sesudah Satu Bulan Terapi Obat Anti Tuberkulosis. Jurnal Laboratorium Medis, 06(01), 18–25.
  10. Kuncara, R. B., SY. Didik Widiyanto, Ririh Jatmi Wikandari, & Wiwit Sulistyasmi. (2024). Differences in Interferon Gamma Levels in Treatment of Tuberculosis in Intensive Phase and Advanced Phase. Jurnal Biosains Pascasarjana, 26(1), 72–76. https://doi.org/10.20473/jbp.v26i1.2024.72-76
  11. Martinot, A. J. (2018). Microbial Offense vs Host Defense: Who Controls the TB Granuloma? Veterinary Pathology, 55(1), 14–26. https://doi.org/10.1177/0300985817705177
  12. Mattos, A. M. M., de Almeida, C. S., Franken, K. L. M. C., de Alves, C. C. S., Abramo, C., de Souza, M. A., L’Hotellier, M., Alves, M. J. M., Ferreira, A. P., Oliveira, S. C., Ottenhoff, T. H. M., & Teixeira, H. C. (2010). Increased IgG1, IFN-γ, TNF-α and IL-6 responses to Mycobacterium tuberculosis antigens in patients with tuberculosis are lower after chemotherapy. International Immunology, 22(9), 775–782. https://doi.org/10.1093/intimm/dxq429
  13. Reichler, M. R., Hirsch, C., Yuan, Y., Khan, A., Dorman, S. E., Schluger, N., Sterling, T. R., Bakhtawar, I., Ledoux, C., McAuley, J., Beison, J., Fitzgerald, M., Naus, M., Nakajima, M., Schluger, N., Hirsch-Moverman, Y., Moran, J., Blumberg, H., Tapia, J., … Luo, C. (2020). Predictive value of TNF-α, IFN-γ, and IL-10 for tuberculosis among recently exposed contacts in the United States and Canada. BMC Infectious Diseases, 20(1), 1–14. https://doi.org/10.1186/s12879-020-05185-2
  14. Salahuddin, N., Ali, F., Hasan, Z., Rao, N., Aqeel, M., & Mahmood, F. (2013). Vitamin D accelerates clinical recovery from tuberculosis: Results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonar. BMC Infectious Diseases, 13(1), 1–11. https://doi.org/10.1186/1471-2334-13-22
  15. Soedarsono, S. (2021). Tuberculosis: Development of New Drugs and Treatment Regimens. Jurnal Respirasi, 7(1), 36. https://doi.org/10.20473/jr.v7-i.1.2021.36-45
  16. Solovic, I., Sester, M., Gomez-Reino, J. J., Rieder, H. L., Ehlers, S., Milburn, H. J., Kampmann, B., Hellmich, B., Groves, R., Schreiber, S., Wallis, R. S., Sotgiu, G., SchoÌlvinck, E. H., Goletti, D., Zellweger, J. P., Diel, R., Carmona, L., Bartalesi, F., Ravn, P., … Lange, C. (2010). Series “update on tuberculosis” edited by C. Lange, M. Raviglione, W.W. Yew and G.B. Migliori number 2 in this series: The risk of tuberculosis related to tumour necrosis factor antagonist therapies: A TBNET consensus statement. European Respiratory Journal, 36(5), 1185–1206. https://doi.org/10.1183/09031936.00028510
  17. Sulistyasmi, W., Almurdi, & Renowati. (2021). Comparing the degree of direct sputum afb smear-positive with the sedimentation in patients suspected of pulmonary tuberculosis. Malaysian Journal of Medicine and Health Sciences, 17(April), 65–67.
  18. Sundaram, K., & Prabhu, V. (2025). Contagious illness of tuberculosis and correlation with various types of cancer. Medicine in Microecology, 24(February), 100123. https://doi.org/10.1016/j.medmic.2025.100123
  19. World Health Organization. (2021). Global Tuberculosis Report 2021: Supplementary Material. In Global tuberculosis report 2021: supplementary material. https://www.who.int/publications/i/item/9789240037021
  20. Wu, H. xia, Xiong, X. feng, Zhu, M., Wei, J., Zhuo, K. quan, & Cheng, D. yun. (2018). Effects of vitamin D supplementation on the outcomes of patients with pulmonary tuberculosis: A systematic review and meta-analysis. BMC Pulmonary Medicine, 18(1), 1–12. https://doi.org/10.1186/s12890-018-0677-6